Amylin Pharmaceuticals – New Version of Byetta

Amylin Pharmaceuticals Inc expects is new longer acting version of Byetta to be available this year.  The drug is called once-weekly exenatide and is being developed by Amylin and Eli Lilly & Co.

A new competitor of Byetta – Novo Nordisk’s Victoza, was approved by the FDA recently and that has given analysts more confidence in the approval of Exenatide.

The new once weekly exenatide is an injectable drug that lasts for a full week and has had impressive results in trials.

Source: Reuters

Related Diabetes Articles

• Novo Nordisk’s Victoza approved - Novo Nordisk’s Victoza has been approved by the US Federal Drugs Administration and could be introduced into the US market within weeks. Share and Enjoy:
• Diabetes increase in older Mexican Americans - Studies from 1993/94 and again in 2004/05 show that type 2 diabetes, which is often linked with obesity has almost doubled in that time for older Mexican Americans. Share and Enjoy:
• Pig Research Offers hope of a cure for type 1 diabetes - Pig cell transplants could provide a cure for type 1 diabetes, with American researchers claiming to have successfully implanted monkeys with pig tissue. One monkey has now been diabetes free for over a year. Share and Enjoy:
• India will be diabetes capital of the world - Indian Heart doctor believes India will become the world capital for diabetes in a few years time. Share and Enjoy:
• The Waist Fat Risk - Many Europeans are oblivious to the risks associated with extra belly fat around the waiste including heart disease and type 2 diabetes. Share and Enjoy: